3 Biotechs Posting Big Moves

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Big moves in biotech today as takeout attempts and trial results dominate the headlines. Let's jump right in a take a look at three biotechs posting big gains.

The top performer is easily Ardea Biosciences (Nasdaq: RDEA  ) , up 52% on news of a buyout from AstraZeneca. The big British pharma makes sense as an acquirer, since AstraZeneca's pipeline is looking mighty barren after a couple of high-profile flops. The $1.26 billion offer is largely for gout drug Lesinurad, although Ardea also has stage 2 cancer assets currently licensed to Bayer. No one confuses Savient's (Nasdaq: SVNT  ) gout drug Krystexxa for a blockbuster, but that doesn't mean Lesinurad is doomed to poor sales as well. Savient unsurprisingly traded down 6% for the day, as it appears the company is running out of time to gain traction for its Krystexxa.

AstraZeneca says more (desperately needed) M&A is on the way and investors should hope that means more targeted deals like Ardea. Overpay on one or two late-stage assets, and it's not the end of the world. A big merger, on the other hand, could end disastrously.

Keryx Pharmaceuticals (Nasdaq: KERX  ) started hot and kept running to a nearly 30% gain on news that Zerenex aced a phase 3 study in the land of the rising sun. Keryx has a lot riding on its late-stage renal disease treatment after its former lead drug perifosine, shared with partner Aeterna Zentaris (Nasdaq: AEZS  ) , met with failure in a phase 3 trial for colon cancer. Zerenex may not have the large market opportunity here, but perifosine is the company's best chance to turn a profit in the near future. It was shown in the Japanese trial to work better than RenaGel. That may be enough to get approved, but Zerenex will need to do better to hold off generic competition when Renagel goes off patent in 2014.

Finally we have Amylin (Nasdaq: AMLN  ) , which hit a new 52-week high today, before closing up 14%. The company purportedly rejected Bristol-Myers Squibb's buyout offer at $22 a share, prompting activist investor Carl Icahn to sue the biotech. Amlyin may have correctly assessed its value, because shares now sit north of $26, as reports emerge that the company is entertaining multiple offers. The sudden enthusiasm comes after ending a sour relationship with Eli Lilly and, more importantly, getting approval for Bydureon, the once-weekly version of twice-a-day diabetes treatment Byetta. If Amylin can generate a bidding war, then the 90% run since Bydureon's approval is far from over.

All of the uncertainty brings big moves to biotech stocks, but investors looking for explosive growth don't need to look any further than a health-care company poised to disrupt the current standard of care with its already approved product. Wall Street hasn't found this small cap stock yet, but you can, by downloading our special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to invest in before the market catches on. Access your report -- it's totally free.

David Williamson holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 24, 2012, at 8:04 AM, earthunit wrote:

    " No one confuses Savient's (Nasdaq: SVNT ) gout drug Krystexxa for a blockbuster, but that doesn't mean Lesinurad is doomed to poor sales as well. Savient unsurprisingly traded down 6% for the day, as it appears the company is running out of time to gain traction for its Krystexxa"

    What kind of an uninformed statement is that?

    Ardea's new gout drug won't even be submitted to FDA for approval until somtime around mid 2014.

    So earliest possible approval is not until 2015!

    THAT is "running out of time for Savient?"

    Secondly, Krystexxa is for a totally different indication than Ardea's new drug would be.

    Krystexxa is used in patients that are refractory or contraindicated to the other gout drugs, including Ardea's, IF it gets approved.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1868819, ~/Articles/ArticleHandler.aspx, 5/30/2016 3:23:12 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 17,873.22 44.93 0.25%
S&P 500 2,099.06 8.96 0.43%
NASD 4,933.51 31.74 0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/27/2016 4:00 PM
AEZS $3.50 Up +0.02 +0.57%
Aeterna Zentaris,… CAPS Rating: *****
AMLN.DL $0.00 Down +0.00 +0.00%
Amylin Pharmaceuti… CAPS Rating: **
KERX $5.86 Up +0.15 +2.63%
Keryx Biopharmaceu… CAPS Rating: **
RDEA.DL $31.96 Down +0.00 +0.00%
Ardea Biosciences,… CAPS Rating: *
SVNTQ $0.00 Down +0.00 +0.00%
Savient Pharmaceut… CAPS Rating: **